Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 24, 2023 - Issue 18
Submit an article Journal homepage
1,884
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia

Ashling Courtneya Sinclair Dermatology, Melbourne, Australia;b Eastern Health Clinical School, Monash University, Victoria, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0694-2379View further author information
ORCID Icon,
Daranporn Triwongwaranta Sinclair Dermatology, Melbourne, Australia;c Department of Dermatology, Siriraj hospital, Mahidol University, Bangkok, ThailandView further author information
,
Ivana Chima Sinclair Dermatology, Melbourne, AustraliaView further author information
,
Samantha Eismana Sinclair Dermatology, Melbourne, AustraliaView further author information
&
Rodney Sinclaira Sinclair Dermatology, Melbourne, Australia;d University of Melbourne, Melbourne, AustraliaView further author information
Pages 1919-1922 | Received 27 Sep 2023, Accepted 03 Nov 2023, Published online: 10 Nov 2023

References

  • Asfour L, Cranwell W, Sinclair R, et al. Male Androgenetic Alopecia. In: Feingold K, Anawalt B Blackman M, editors. Endotext. South Dartmouth (MA): MDText.com, Inc; 2000. Copyright © 2000-2023, MDText.com, Inc.;
  • Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol. 2001 Sep;45(3 Suppl):S81–6. doi: 10.1067/mjd.2001.117428
  • Sinclair R. Fortnightly review: male pattern androgenetic alopecia. BMJ. 1998 Sep 26;317(7162):865–869. doi: 10.1136/bmj.317.7162.865
  • Kasprzak M, Sicińska J, Sinclair R. The trichoscopy derived Sinclair scale: enhancing visual assessment through quantitative trichoscopy. Australas J Dermatol. 2019;60(2):60;134–136. doi: 10.1111/ajd.12964
  • Gilmore S, Sinclair R. Chronic telogen effluvium is due to a reduction in the variance of anagen duration. Aust J Dermatol. 2010;50(3):163–167. doi: 10.1111/j.1440-0960.2010.00654.x
  • Asfour L, Blume-Peytavi U, Bokhari L, et al. You cannot go bald without first, losing your hair: telogen effluvium is a precursor to, prerequisite for and incitant to common baldness in men. J Am Acad Dermatol. 2023. (In press)
  • Boyapati A, Sinclair R. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia. Australas J Dermatol. 2013 Feb;54(1):49–51. doi: 10.1111/j.1440-0960.2012.00909.x
  • Windahl SH, Andersson N, Börjesson AE, et al. Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice. PLoS One. 2011;6(6):e21402
  • Imperato-McGinley J, Peterson RE, Gautier T, et al. Male pseudohermaphroditism secondary to 5 alpha-reductase deficiency–a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity. J Steroid Biochem. 1979 Jul;11(1b):637–645. doi: 10.1016/0022-4731(79)90093-1
  • Kiguradze T, Temps WH, Yarnold PR, et al. Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020. doi: 10.7717/peerj.3020
  • Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J DermatolTreat. 2022 Nov;33(7):2946–2962. doi: 10.1080/09546634.2022.2109567
  • Unger JM, Till C, Thompson IM, et al. Long-term consequences of finasteride vs placebo in the prostate cancer prevention trial. JNCI. 2016 Aug 26;108(12):djw168. doi: 10.1093/jnci/djw168
  • Saceda-Corralo D, Moustafa F, Moreno-Arrones Ó, et al. Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice. J Drugs Dermatol. 2022 Jul 1;21(7):742–747. doi: 10.36849/JDD.6610
  • Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286–294. doi: 10.1111/jdv.17738

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.